Infant Bacterial Therapeutics vs ChromaCode
Side-by-side comparison of AI visibility scores, market position, and capabilities
Infant Bacterial Therapeutics (IBT) is developing live biotherapeutic Lactobacillus reuteri DSM17938 for necrotizing enterocolitis prevention in premature infants, with Phase 3 trial results expected in 2026.
About
Infant Bacterial Therapeutics (IBT) is a Swedish biopharma company developing Lactobacillus reuteri DSM17938 — a probiotic bacterial strain — as a regulated drug (live biotherapeutic product) to prevent necrotizing enterocolitis (NEC) in premature infants. NEC is a devastating gastrointestinal emergency affecting 1–7% of premature newborns, with 30% mortality and severe long-term outcomes in survivors. No approved preventive treatments exist, despite decades of evidence suggesting certain probiotic strains reduce NEC incidence.
ChromaCode develops HDPCR technology enabling standard PCR instruments to run highly multiplexed molecular diagnostic assays for infectious disease, oncology, and genetic testing at lower cost.
About
ChromaCode is a molecular diagnostics company developing High-Definition PCR (HDPCR), a breakthrough multiplexing platform that dramatically expands the number of analytes detectable in a single PCR well using standard laboratory instruments. By combining proprietary chemistry with amplitude modulation, multi-spectral encoding, and cloud-based decoding software, HDPCR enables labs to run panels for infectious disease, oncology biomarkers, transplant monitoring, and prenatal testing without expensive new hardware.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.